<DOC>
	<DOCNO>NCT02286089</DOCNO>
	<brief_summary>The main objective study evaluation safety tolerability OpRegen - human embryonic stem cell-derived retinal pigment epithelial ( RPE ) cell . The study also include initial exploration ability transplant OpRegen cell engraft , survive , moderate disease progression .</brief_summary>
	<brief_title>Safety Efficacy Study OpRegen Treatment Advanced Dry-Form Age-Related Macular Degeneration</brief_title>
	<detailed_description>OpRegenÂ® cell-based product compose retinal pigment epithelial ( RPE ) cell , derive human embryonic stem cell ( hESC ) administer cell suspension ophthalmic Balanced Salt Solution Plus ( BSS Plus ) . This Phase I/IIa , dose-escalation , single-center study , evaluate safety tolerability OpRegen transplantation patient progressive dry-AMD . The study include also initial exploration efficacy . A total 15 patient enrol . The patient 50 year age old , non-neovascular ( dry ) AMD , funduscopic finding GA macula , absence additional concomitant ocular disorder . The patient divide four cohort , accord best correct visual acuity ( BCVA ) administrate OpRegen dose .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<criteria>1 . Age 50 old ; 2 . Diagnosis dry ( nonneovascular ) age relate macular degeneration eye ; 3 . Funduscopic finding dry AMD progressive geographic atrophy macula , 0.5 disc area ( 1.25mm^2 17 mm^2 ) size study eye 0.5 disc area fellow eye ; 4 . Best corrected central visual acuity equal le 20/200 cohort 13 equal less 20/100 cohort 4 study eye ETDRS vision test ; 5 . Vision nonoperated eye must better equal operated eye ; 6 . Patients sufficiently good health allow participation studyrelated procedure complete study follow period ( medical record ) ; 7 . Ability undergo vitreoretinal surgical procedure monitor anesthesia care ; 8 . Blood count , blood chemistry , coagulation urinalysis without abnormal significance ; 9 . Negative HIV , HBC , HCV , negative CMV IgM EBV IgM ; 10 . Patients current history malignancy ( exception successfully treat basal/squamous cell carcinoma skin ) base age match screen exam ( discretion study physician ) ; 11 . Willing defer future blood tissue donation ; 12 . Able understand willing sign inform consent . 1 . Evidence neovascular AMD history , well clinical exam , fluorescein angiography ( FA ) , ocular coherence tomography ( OCT ) baseline either eye ; 2 . History presence diabetic retinopathy , vascular occlusion , uveitis , Coat 's disease , glaucoma , cataract medium opacity prevent posterior pole visualization significant ocular disease AMD compromise could compromise vision study eye confound analysis primary outcome ; 3 . History retinal detachment repair study eye ; 4 . Axial myopia great 6 diopter ; 5 . Cataract Surgery study eye past 6 week ocular surgery study eye past 3 month 6 . History cognitive impairment dementia ; 7 . Contraindication systemic immunosuppression ; 8 . History condition AMD associate choroidal neovascularization study eye ( e.g . pathologic myopia presume ocular histoplasmosis ) ; 9 . Active history follow disease : cancer , renal disease , myocardial infraction previous 12 month , immunodeficiency ; 10 . Female ; pregnancy lactation ; 11 . Current participation another clinical study . Past participation ( within 6 month ) clinical study drug administer systemically eye . 12 . Currently receive aspirin , aspirin contain product and/or coagulation modify drug discontinue 7 day prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>dry-AMD</keyword>
	<keyword>Geographic Atrophy</keyword>
</DOC>